尿液外泌体基因表达面板可区分活检中惰性与侵袭性前列腺癌
本研究从接受诊断性活检患者的首段非指检尿液中提取外泌体RNA,建立基于微滴数字PCR的定量表达检测,评估2基因面板(PCA3、PCGEM1)联合标准诊疗变量预测活检高级别前列腺癌(Gleason评分7-10)的性能。在种族多样队列中,联合模型预测高级别癌的AUC为0.88,显著优于标准诊疗变量单独使用的0.80(p=0.016),决策曲线分析显示采用基因面板有临床获益。
要点
- 尿液外泌体2基因面板(PCA3、PCGEM1)联合标准变量可提升高级别前列腺癌预测。
- 联合模型预测高级别癌AUC 0.88,优于标准诊疗变量单独AUC 0.80(p=0.016)。
- 决策曲线分析显示采用基因面板检测高级别癌较标准诊疗 alone 有获益。
核心结论
- 尿液外泌体2基因面板联合标准诊疗变量可显著改善活检时高级别前列腺癌的预测。
研究设计与样本
- 研究收集接受诊断性活检患者的首段非指检尿液标本,从尿液外泌体提取总RNA。
- 开发基于微滴数字PCR的定量表达检测方案,检测尿液外泌体mRNA中的候选基因。
- 在种族多样患者队列中评估基因表达检测预测活检高级别癌(Gleason评分7-10)对比低级别癌(Gleason评分6)和癌阴性病例的临床性能。
主要发现
- 2基因面板(PCA3、PCGEM1)联合标准诊疗变量预测高级别癌的AUC为0.88,标准诊疗变量单独为0.80,差异显著(p=0.016)。
- 决策曲线分析显示采用基因面板检测高级别癌较标准诊疗 alone 有获益。
关键数值与推荐
- 高级别前列腺癌定义为Gleason评分7-10,低级别癌定义为Gleason评分6。
- 联合模型预测高级别癌AUC 0.88 vs 标准诊疗变量单独AUC 0.80,p=0.016。
临床怎么用
- 该尿液外泌体基因表达检测平台有潜力作为无创工具,辅助活检时区分惰性与侵袭性前列腺癌。
- 联合标准诊疗变量使用可改善高级别癌的风险预测,决策曲线分析支持其临床获益。
局限性
- 研究为诊断性检测开发与评估,样本来自接受活检的患者队列,需进一步外部验证。
- 原文未报告检测的具体阈值、重复性数据及长期随访结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer is predominantly indolent at diagnosis with a small fraction (15% to 25%) representing aggressive subtype (Gleason score 7-10), which is prone to metastatic progression. It is critical to explore noninvasive assays for the early detection of this aggressive subtype, when it still can be treated effectively. Additionally, there is an emerging need to develop markers that perform equally well across races, as racial differences in the prevalence and mortality of prostate cancer has become evident. MATERIALS AND METHODS: First catch, nondigital rectal examination urine specimens were collected from patients undergoing diagnostic biopsy. Total RNA was extracted from urinary exosomes and a quantitative expression assay protocol using droplet digital polymerase chain reaction was developed for detection of candidate genes in exosomal mRNAs from urine. Clinical performance for the gene expression assay was evaluated to predict high grade cancer (Gleason score 7-10) from low grade cancer (Gleason score 6) and cancer negative cases at biopsy. Assay performance was examined in combination with standard of care to determine improvement in model prediction. RESULTS: In a racially diverse patient cohort a 2-gene panel (PCA3, PCGEM1), in combination with standard of care variables, significantly improved the prediction of high grade cancer at diagnosis compared to standard of care variables alone (AUC 0.88 vs 0.80, respectively, p=0.016). Decision curve analysis showed that there is a benefit of adopting the gene panel for detection of high grade cancer compared to standard of care alone. CONCLUSIONS: This study highlights the potential for developing broadly applicable prostate cancer diagnostic biomarker panels for aggressive prostate cancer using our novel gene expression assay platform.
引用
- Kohaar I, Chen Y, Banerjee S, et al. A Urine Exosome Gene Expression Panel Distinguishes between Indolent and Aggressive Prostate Cancers at Biopsy. J Urol. 2020. PMID: 32945736. doi:10.1097/JU.0000000000001374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。